Study Design and Objectives

This is a 12‑month, non‑comparative, non‑interventional observational study that commenced on September 10, 2024, and is being conducted across multiple sites in Russia. Patient‑reported outcomes following Tezepelumab treatment are collected in routine clinical practice settings. The aim is to generate real‑world data post‑reimbursement to confirm the therapy’s effectiveness and safety.

Patient Population and Primary Endpoints

The study enrolls patients with severe asthma irrespective of phenotype. While existing biologics are often restricted based on eosinophil counts, Tezepelumab suppresses upstream inflammatory pathways, allowing inclusion of a broader patient cohort. The primary endpoints are patient‑reported outcomes and the degree of symptom improvement.

Current Treatment Landscape and Differentiation

In Russia, Tezepelumab has recently received reimbursement approval, leading to expanded utilization. Conventional therapies rely on specific biomarkers to restrict patient eligibility, whereas Tezepelumab blocks multiple inflammatory mediators, offering phenotype‑agnostic treatment. This is expected to improve access to therapy and generate cost‑savings for the healthcare system.

Industry Impact

Real‑world evidence is a critical input for regulators and payers assessing therapeutic value. Positive results could facilitate adoption of the same treatment model in neighboring countries as well as Russia, providing a favorable signal for AstraZeneca’s revenue growth and market‑share expansion.

Investor Implications

Even as an observational study, demonstrating efficacy in a real‑world patient population enhances the long‑term value of the drug. This reduces risk exposure for investors in biotech portfolios and raises expectations for future pipeline expansion.